Lupus en Argentina. Pacientes no respondedores al tratamiento estándar y belimumab como posible opción. Datos del registro RELESSAR
Resumen
Introducción: el lupus es una enfermedad compleja y varias veces de difícil abordaje. Alcanzar la remisión es uno de los objetivos, incorporando opciones terapéuticas. Objetivos: describir las características generales de los pacientes según el estado de la enfermedad y el uso de belimumab. Materiales y métodos: estudio de corte transversal, registro RELESSAR. Se definió el estado de la enfermedad como: remisión: SLEDAI=0 y sin corticoides; baja actividad de la enfermedad: SLEDAI >0 y ≤4 y sin corticoides; control no óptimo: SLEDAI >4 y cualquier dosis de corticoides. Resultados: se incluyeron 1.277 pacientes, 23,4% en remisión, 12,6% en baja actividad y 63,8% con control no óptimo. En este último grupo eran más jóvenes y con menor duración de la enfermedad; presentaban mayores índices de actividad y cronicidad, y mayor empleo de inmunosupresores. Solo el 22,3% de los pacientes con criterio potencial de uso de belimumab (lupus eritematoso sistémico activo a pesar del tratamiento estándar) lo recibía en ese momento. Las variables asociadas a hospitalizaciones fueron: terapia con corticoides, ciclofosfamida y mayor SLICC. Conclusiones: se refleja la complejidad del manejo de estos pacientes y se visualizan aspectos estructurales como la desigualdad. El uso del belimumab resultaría beneficioso en los pacientes seleccionados.Citas
I. Mucke J, Fischer-Betz R, Schneider M. State of the art: systemic lupus erythematosus. Z Rheumatologie 2019;78(6):500-510.
II. Mok CC. Treat-to-target in systemic lupus erythema- tosus: Are we there yet? Expert Rev Clin Pharmacol 2016;9(5).
III. Morand EF, Mosca M. Treat to target, remission and low disease activity in SLE. Best Pract Res Clin Rheumatol 2017;31(3):342-350.
IV. Golder V, Tsang-A-Sjoe MWP. Treatment targets in SLE: Remission and low disease activity state. Rheumatol (United Kingdom)2020;59.
V. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (United King- dom) 2020;59(Suppl5):v69-v81.
VI. Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimi- zing outcome in SLE: Treating-to-target and de nition of treatment goals. Autoimmun Rev 2014;13(7):770-7.
VII. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 Update of the EULAR recommendations for the management of systemic lu- pus erythematosus. Ann Rheum Dis 2919;78(6):736-745.
VIII. Morand E, Golder V, Kandane-Rathnayake R, Huq M, Nim H, Louthrenoo W, et al. Comparison of effects of DORIS remission and lupus low disease activity state (LLDAS) on disease outcomes in a multinational pros- pective study. Resumen del International Congress on Systemic Lupus Erythematosus (LUPUS 2019), San Fran- cisco, California, United States of America.
IX. Van Vollenhoven R, Bertsias G, Doria A, Isenberg D, Mo- rand EF, Petri MA, et al. 2021 DORIS de nition of remis- sion in SLE: nal recommendations from an internatio- nal task force. Lupus Sci Med 2021 Nov;8(1):e000538.
X. Van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, et al. A framework for remission in SLE: consensus ndings from a large international task force on de nitions of remission in SLE (DORIS). Ann Rheum Dis 76(3):554-61.
XI. Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythe- matosus. J Clin Invest 2009;119(5).
XII. Harvey PR, Gordon C. B-cell targeted therapies in sys- temic lupus erythematosus: Successes and challenges. BioDrugs 2013;27(2).
XIII. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzo- vá D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhi- bits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(12).
XIV. Van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of sys- temic lupus erythematosus: High disease activity pre- dictors of response. Ann Rheum Dis 2012;71(8).
XV. Babini A, Cappuccio AM, Caprarulo C, Casado G, Eimon A, Figueredo H, et al. Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a cli- nical practice setting: Results from a 24-month OBSEr- ve study in Argentina. Lupus 2020;29(11).
XVI. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classi cation of systemic lupus erythematosus. Arthritis Rheum 1997;40(9):1725.
XVII. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jiménez RE, et al. BLISS-52 Study Group. Ef cacy and sa- fety of belimumab in patients with active systemic lu- pus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
XVIII. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzo- vá D, et al. BLISS-76 Study Group. A phase iii, randomi- zed, placebocontrolled study of belimumab, a monoclo- nal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
XIX. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35(6):630-40.
XX. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30(9):1955-9.
XXI. Charlson M, Szatrowski TP, Peterson J, Gold J. Valida- tion of a combined comorbidity index. J Clin Epidemiol 1994;47(11).
XXII. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Quintana R, Gómez-Puerta, AJ, et al. Predictors of remission and low disease activity state in systemic lupus erythematosus: data from a multi-ethnic, multinational Latin-Ameri- can Lupus Cohort. J rheumatol 2019;46(10).
XXIII. Polachek A, Gladman DD, Su J, Urowitz MB. De ning low disease activity in systemic lupus erythematosus. Ar- thritis Care Res 2017;69(7).
XIV. Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirar- dello A, et al. Prolonged remission in caucasian patients with SLE: Prevalence and outcomes. Ann Rheum Dis 2015;74(12).
XXV. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Catoggio LJ, Drenkard C, Sarano J, et al. Remission and low disea- se activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multi- national Latin American Lupus Cohort (GLADEL). Ann Rheum Dis 76(12):2071-4.
XXVI. Steiman AJ, Urowitz MB, Ibanez D, Papneja A, Gladman DD. Prolonged clinical remission in patients with syste- mic lupus erythematosus. J Rheumatol 2014;41(9).
XXVII. Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, Voskuyl AE. Both prolonged remission and lupus low disease activity state are associated with reduced damage ac- crual in systemic lupus erythematosus. Rheumatology (Oxford) 2017;56(1).
XXVIII. Fernández M, Alarcón GS, Calvo-Alén J, Andrade R, McGwin G, Vilá LM, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007;57(4).
XXIX. Sandhu VK, Teh P, Zakhary B, Liu J. The Southern Cali- fornia Lupus Registry: I. Baseline characteristics of lu- pus patients in uncharted territory. Lupus 2020;29(10).
XXX. Parodis I, Johansson P, Gómez A, Soukka S, Emamikia S, Chatzidionysiou K. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatol (United Kingdom) 2019;58(12).
XXXI. Bruce IN, Urowitz M, Van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, et al. Long-term organ damage accrual and safety in patients with SLE treated with be- limumab plus standard of care. Lupus 2016;25(7).
XXXII. Collins CE, Cortes-Hernández J, García MA, von Kempis J, Schwarting A, Touma Z, et al. Real-world effective- ness of belimumab in the treatment of systemic lupus erythematosus: oooled analysis of multi-country data from the OBSErve Studies. Rheumatol Ther 2020;7(4).
XXXIII. Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, et al. Belimumab use, clinical outcomes and glu- cocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical prac- tice settings: results from the OBSErve Canada Study. Rheumatol Int 2017;37(6).
XXXIV. Liang H, Pan HF, Tao JH, Ye DQ. Causes and factors associated with frequent hospitalization in Chinese pa- tients with systemic lupus erythematosus: An ambis- pective cohort study. Med Sci Monit 2019;25.
XXXV. Petri M, Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: A prospective study of the Hopkins Lupus Cohort. J Rheu- matol 1992;19(10).
XXXVI. Lee JW, Park DJ, Kang JH, Choi SE, Yim YR, Kim JE, et al. The rate of and risk factors for frequent hospitalization in systemic lupus erythematosus: Results from the Ko- rean lupus network registry. Lupus 2016;25(13).
XXXVII. Gu K, Gladman DD, Su J, Urowitz MB. Hospitalizations in patients with systemic lupus erythematosus in an Aca- demic Health Science Center. J Rheumatol 2017;44(8).
XXXVIII. Busch RW, Kay SD, Voss A. Hospitalizations among Da- nish SLE patients: a prospective study on incidence, causes of admission and risk factors in a population- based cohort. Lupus 2018;27(1).
XXXIX. Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005;14(11):890-5.
XL. González-Echavarri C, Capdevila O, Espinosa G, Suárez S, Marín-Ballvé A, González-León R, et al. Infections in newly diagnosed Spanish patients with systemic lu- pus erythematosus: data from the RELES cohort. Lupus 2018;27(14).
XLI. Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey GB, Wojdyla D, Pons-Estel GJ, Quintana R, et al. Factors predictive of serious infections over time in systemic lupus erythe- matosus patients: data from a multi-ethnic, multi-natio- nal, Latin American lupus cohort. Lupus 28(9):1101-10.
XLII. Cortés J, Andreu JL, Calvo J, García-Aparicio AM, Coro- nell CG, Díaz-Cerezo S. Evaluation of use of belimumab in clinical practice settings (observe study) In Spain: Health Resource Utilization and Labour Absenteeism. Value Heal 2014;17(7).
XLIII. Cortes J, Marras C, Andreu JL, Calvo-Alen J, García-Aparicio AM, Álvarez Diez E, et al. Evolution of patients with syste- mic lupus erythematous treated with belimumab in clini- cal practice settings. 2014 ACR/ARHP Annu Meet. 2014.
XLIV. Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH, et al. Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medica- tions. Arthritis Rheumatol 2017;69(2).
XLV. Simard J, Rossides M, Arkema E. S5D:6 Serious infection rates in systemic lupus erythematosus: a swedish po- pulation-based assessment. Lupus Science & Medicine 2018;5.
XLVI. Simard JF, Rossides M, Gunnarsson I, Svenungsson E, Arkema E V. Infection hospitalisation in systemic lupus in Sweden. Lupus Sci Med 2021;8(1).
XLVI. Pons-Estel GJ, Alarcon GS, Hachuel L, Boggio G, Wojdyla D, Pascual-Ramos V, et al. Anti-malarials exert a pro- tective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin- American cohort. Rheumatol 2012;51(7):1293-8.
XLVIII. Prata AR, Luís M, Assunção H, da Silva JAP, Inês LS. Anti- malarial treatment and minimizing prednisolone are as- sociated with lower risk of infection in SLE: a 24-month prospective cohort study. Clin Rheumatol 2021.
XLIX. Ugarte A, Danza A, Ruiz-Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol 2018;30(5).
Derechos de autor 2022 a nombre de los autores. Derechos de reproducción: Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
